Glaukos Corp (NYSE:GKOS) — Market Cap & Net Worth
Market Cap & Net Worth: Glaukos Corp (GKOS)
Glaukos Corp (NYSE:GKOS) has a market capitalization of $7.84 Billion ($7.84 Billion) as of August 7, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #2659 globally and #955 in its home market, demonstrating a 12.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Glaukos Corp's stock price $170.93 by its total outstanding shares 58733911 (58.73 Million). See GKOS capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Glaukos Corp Market Cap History: 2015 to 2026
Glaukos Corp's market capitalization history from 2015 to 2026. Data shows growth from $1.45 Billion to $10.04 Billion (20.40% CAGR).
Index Memberships
Glaukos Corp is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P Small-Cap 600 Index
SML
|
$1.61 Trillion | 0.43% | #23 of 602 |
Weight: Glaukos Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Glaukos Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Glaukos Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.07x
Glaukos Corp's market cap is 13.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.01 Billion | $114.40 Million | $4.52 Million | 17.61x | 445.50x |
| 2017 | $1.51 Billion | $159.25 Million | -$92.00K | 9.46x | N/A |
| 2018 | $3.30 Billion | $181.28 Million | -$12.95 Million | 18.20x | N/A |
| 2019 | $3.20 Billion | $236.98 Million | $15.42 Million | 13.50x | 207.42x |
| 2020 | $4.42 Billion | $224.96 Million | -$120.35 Million | 19.65x | N/A |
| 2021 | $2.61 Billion | $294.01 Million | -$49.59 Million | 8.88x | N/A |
| 2022 | $2.57 Billion | $282.86 Million | -$99.19 Million | 9.07x | N/A |
| 2023 | $4.67 Billion | $314.71 Million | -$134.66 Million | 14.84x | N/A |
| 2024 | $8.81 Billion | $383.48 Million | -$146.37 Million | 22.96x | N/A |
| 2025 | $6.63 Billion | $507.44 Million | -$187.69 Million | 13.07x | N/A |
Competitor Companies of GKOS by Market Capitalization
Companies near Glaukos Corp in the global market cap rankings as of August 7, 2026.
Key companies related to Glaukos Corp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #117 globally with a market cap of $183.82 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #184 globally with a market cap of $128.98 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #234 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #240 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #117 | Abbott Laboratories | NYSE:ABT | $183.82 Billion | $105.71 |
| #184 | Stryker Corporation | NYSE:SYK | $128.98 Billion | $337.03 |
| #234 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #240 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $85.99 |
Glaukos Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Glaukos Corp's market cap moved from $1.45 Billion to $ 10.04 Billion, with a yearly change of 20.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.04 Billion | +51.39% |
| 2025 | $6.63 Billion | -24.70% |
| 2024 | $8.81 Billion | +88.63% |
| 2023 | $4.67 Billion | +81.98% |
| 2022 | $2.57 Billion | -1.71% |
| 2021 | $2.61 Billion | -40.95% |
| 2020 | $4.42 Billion | +38.17% |
| 2019 | $3.20 Billion | -3.03% |
| 2018 | $3.30 Billion | +118.99% |
| 2017 | $1.51 Billion | -25.22% |
| 2016 | $2.01 Billion | +38.92% |
| 2015 | $1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Glaukos Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.84 Billion USD |
| MoneyControl | $7.84 Billion USD |
| MarketWatch | $7.84 Billion USD |
| marketcap.company | $7.84 Billion USD |
| Reuters | $7.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more